Association between anticardiolipins and anti B2 glycoprotein 1 and preclampsia before 35 gestational weeks
DOI:
https://doi.org/10.18597/rcog.745Keywords:
Preeclampsia, Anticardiolipin, b2 Glycoprotein I, AntiphospholipidsAbstract
Objective: To explore association between Inmunoglobulins G Anticardiolipina and Anti b2 Glycoprotein I with Preeclampsia and related complications before 35 weeks of pregnancy.
Methodology: Case control prospective descriptive study with 55 preeclamptics and 55 non preeclamptics pregnant patients before 35 weeks of gestational age at The Hospital Universitario San Vicente de Paúl and Hospital General de Medellín, between September 1° -1999 and September 1° -2000.
Results: Over a one year period we studied 55 preeclamptic patients (90,9% severe) for ACA and Ab2GP I and its relation with attributable complications; comparison was made with 54 non-preeclamptic pregnant patients. There were no significative differences in the general characteristics of the patients.1/55 case has Ab2GP I vs. 5/54 control (P=0.09 ns ). 7/55 cases had positive titles for AC vs. 11/54 controls (P=0.47 ns ). (Interpretation by house factoring recommendation). 24/55 cases resulted positives for AC vs. 30/54 controls (P=0,48 ns) Interpretation by international guide) (AC1). 25/55 cases of Fetal Growth Restriction were not associated to the antibodies AC,AC1 nor Ab2GP I. From fourteen cases with severe complications (Hellp, abruptio, pulmonary edema, etc.) none were related to the studied antibodies.
None of the controls presented PE; one of positives was complicated by pulmonary embolism but related to mitral estenosis.
Conclusion: There is not an association between preeclampsia before 35 weeks and related complications and Ab2GP I or AC.
Author Biographies
Jorge Mario Gómez Jiménez
Héctor Iván García García
Jáder Gómez Gallego
Alejandro Quintero Galeano
Clara María Mesa Restrepo
Natalia Aguirre
References
E.U. Population Reference Bureau (PRB). Resumen de las conclusiones del Consejo Nacional de Investigación de la Academia Nacional de Ciencias de los E.U. "Cómo mejorar la salud reproductiva de los países en desarrollo". Washington. Oct. 1997.
Presidencia de la República, Departamento Nacional de Planeación, Ministerio de Salud y otros. "Mortalidad Materna en Colombia". Santafé de Bogotá, agosto 1996.
Ness R, Roberts JM. Heterogeneous causes constituting the single syndrome of Preeclampsia: A hypothesis and its implications. Am J Obstet Gynecol 1996; 175: 1365-70.
Lockwood CJ, Rand J. The Immunobiology and Obstetrical Consequences of Antiphospholipid Antibodies. Obstet Gynecol Survey. 1994; 49: 432-40.
Dekker G, de Vries J, Doelitzsch P, et al. Underlying disorders associated with severe early-onset preeclampsia. Am J Obstet Gynecol 1995; 173: 1042-8.
Harris E, Spinnato J. Should anticardiolipin tests be performed in otherwise healthy pregnant women? Am J Obstet Gynecol 1991;165 part 1: 1272-77.
El-Roely A, Collicher N. Definition of Normal Autoantibody leves in apparently healthy population. Obstet Gynecol 1988; 72: 596-602.
Fields RA, Toubbeh H, Scarles RP. The Prevalence of the Anticardiolipin antibodies in healthy elderly population and its association with antinuclear antibodies. J Rheumatol. 1989; 16: 623-25.
The Anticardiolipin Wet Workshop. Fifth International Symposium on Antiphospholipid Antibodies, San Antonio, Sept 13, 1992.
Branch D, Andrés R, Digre K, et al. The association of Antiphospholipid Antibodies With Severe Preeclampsia. Obstet Gynecol 1989; 73: 541-45.
Yasuda M, Takakuwa K, Tokunaga A, Tanaka K. Prospective Studies of the Association between Anticardiolipin Antibody and Outcome of Pregnancy. Obstet Gynecol 1995; 86: 555-9.
Petri M, Rheinschmidt M, Whitting-O'Keete Q, et al. The Frequency of Lupus Anticoagulant in Systemic Lupus Erytemathousus. Ann Intern Med 1987; 106: 524-531.
Matsuura E, Igarashi Y, Fujimoto M, et al. Improved enzyme immunoassay for anticardiolipin antibody: A highly specific assay for antiphospholipid syndrome. Clin Exp Rheumatol 1990; 8: 204.
Galli M. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. The Lancet 1990; 335: 1544-47.
Matsuura E, Igarashi Y, Fujimoto M, et al. Heterogeneity anticardiolipin antibodies defined by the anticardiolipin cofactor. J. Immunol 1992; 148: 3885-91.
Katano K, Aoki K, Sasa H, et al. B2-Glycoprotein I dependent anticardiolipin antibodies as a predictor of adverse pregnancy outcomes in healthy pregnant women. Hum Reprod 1996; 11: 509-12.
Faden D. Anti-beta 2 glycoprotein I antibodies in a general obstetric population: preliminary results on the prevalence and correlation with pregnancy outcome. Anti-b2 glycoprotein I antibodies are associated with some obstetrical complications, mainly preeclampsia-eclampsia. Europ Jour Obstet Gynecol Reprod Biol 1997; 73: 37- 421.
Hadlock FP, Harrist RB, Martínez-Poyer J. In uterus analysis of fetal growth: A sonographic weights standar.Radiology 1991; 181: 129-33.
Kupferminc M, Eldor A, Steinman N, et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med 1999; 340: 9-13.
Pampus van MG, Wolf H, Buller HR, et al. Underlying disorders associated with severe preeclampsia and hellp syndrome. Am J Obstet Gynecol 1997; 175: s26 (Abstracts SPO 1997).
Rajah SB, Moodley J, Pudifin D, et al. Anticardiolipin antibodies in Hypertensive emergencies. Clin and exper hypertens pregnancy 1990; B9: 267-27.
Out HJ, Bruinse HW, Christiaens GCML, et al. A prospective, controlled multicenter study on the obstetric risks of pregnant women with antiphospholipid antibodies. Am J Obstet Gynecol 1992; 167: 26-32.
How to Cite
Downloads
Downloads
Published
Issue
Section
| Article metrics | |
|---|---|
| Abstract views | |
| Galley vies | |
| PDF Views | |
| HTML views | |
| Other views | |
